abrdn Life Sciences Investors
Sponsor: abrdn · Inception May 1, 1992 · Pays quarterly
Market priceShare price
$17.24
+0.58% (+$0.10)
NAVAsset value per share
$17.86
as of Oct 13, 2026 · Nasdaq NAV symbol
Premium / discountPrice vs. assets
3.47% discount *
Indicative: latest price vs latest reported NAV
Distribution rate (price)Payout rate
14.39%
regular, annualised · on NAV 13.89%
Expense ratioAnnual cost
Not reported
no tagged fee table
LeverageBorrowing
Not reported
senior securities not tagged
Quote status: Market closed — last regular-session price · last trade Oct 15, 2026, 4:00 PM EDT (exchange time, ET) · retrieved Oct 15, 2026, 5:45 PM EDTRegular-session prices; extended-hours quotes are not displayed.
Full portfolio as filed on SEC Form N-PORT for the month ending Jun 30, 2026, filed Aug 28, 2026. 145 positions; weights are percent of net assets as reported. Weights sum to 100.0% — leverage, cash, derivatives and short positions mean totals need not equal 100%. This is a historical report, not a live portfolio.
Top 10 holdings
| # | Security | Type | Country | Weight | Value (USD) |
|---|---|---|---|---|---|
| 1 | uniQure NV | Equity | Netherlands | 3.77% | $26M |
| 2 | Insmed Inc | Equity | United States | 3.22% | $22.2M |
| 3 | VeraDermics Inc | Equity | United States | 3.06% | $21.1M |
| 4 | Personalis Inc | Equity | United States | 3.00% | $20.7M |
| 5 | Argenx SE | Equity | Netherlands | 2.64% | $18.2M |
| 6 | Dyne Therapeutics Inc | Equity | United States | 2.58% | $17.8M |
| 7 | Denali Therapeutics Inc | Equity | United States | 2.45% | $16.9M |
| 8 | VERADERMICS, INC. | Preferred | United States | 1.95% | $13.4M |
| 9 | Abivax SA | Equity | France | 1.89% | $13.1M |
| 10 | Immunovant Inc | Equity | United States | 1.88% | $13M |
Asset class
| Asset class | % net assets | Value |
|---|---|---|
| Equity (common) | 88.92% | $613M |
| Equity (preferred) | 6.72% | $46.4M |
| Derivative (equity) | 2.70% | $18.6M |
| Short-term investment vehicle | 1.34% | $9.2M |
| Debt | 0.26% | $1.8M |
| ABS (other) | 0.06% | $441K |
Country (top 12)
| Country (top 12) | % net assets | Value |
|---|---|---|
| United States | 82.43% | $568M |
| Netherlands | 8.59% | $59.3M |
| France | 2.49% | $17.2M |
| Canada | 2.04% | $14.1M |
| Cayman Islands | 1.26% | $8.7M |
| Ireland | 0.81% | $5.6M |
| British Virgin Islands | 0.79% | $5.4M |
| Switzerland | 0.65% | $4.5M |
| Denmark | 0.45% | $3.1M |
| Belgium | 0.32% | $2.2M |
| Singapore | 0.15% | $1M |
| Israel | 0.02% | $167K |
Region
| Region | % net assets | Value |
|---|---|---|
| United States | 82.43% | $568M |
| Offshore domiciles | 2.05% | $14.1M |
| Canada | 2.04% | $14.1M |
| Developed Europe | 13.31% | $91.8M |
| Asia ex-Japan | 0.15% | $1M |
| Middle East | 0.02% | $167K |
Issuer type
| Issuer type | % net assets | Value |
|---|---|---|
| Corporate | 96.29% | $664M |
| Other | 2.70% | $18.6M |
| Registered fund | 1.01% | $7M |
Fair-value level
| Fair-value level | % net assets | Value |
|---|---|---|
| Level 1 | 93.33% | $644M |
| Level 3 | 6.59% | $45.4M |
| Level 2 | 0.08% | $519K |
Level 3 = valued with unobservable inputs (typically private or illiquid).
Long / short
| Long / short | % net assets | Value |
|---|---|---|
| Long | 97.30% | $671M |
| N/A | 2.70% | $18.6M |
All allocation percentages use net assets as the denominator (N-PORT convention). A position's share of invested assets may differ from its share of the whole fund including cash and leverage.
All 145 positions
| Security | Identifier | Type | Issuer | Country | Balance | Units | Value (USD) | Weight | FV level |
|---|---|---|---|---|---|---|---|---|---|
| uniQure NV | NL0010696654 | Equity | CORP | Netherlands | 564,239 | shares | $26M | 3.77% | 1 |
| Insmed Inc | 457669307 | Equity | CORP | United States | 208,079 | shares | $22.2M | 3.22% | 1 |
| VeraDermics Inc | 922967104 | Equity | CORP | United States | 171,383 | shares | $21.1M | 3.06% | 1 |
| Personalis Inc | 71535D106 | Equity | CORP | United States | 1,542,774 | shares | $20.7M | 3.00% | 1 |
| Argenx SE | 04016X101 | Equity | CORP | Netherlands | 19,643 | shares | $18.2M | 2.64% | 1 |
| Dyne Therapeutics Inc | 26818M108 | Equity | CORP | United States | 799,847 | shares | $17.8M | 2.58% | 1 |
| Denali Therapeutics Inc | 24823R105 | Equity | CORP | United States | 658,067 | shares | $16.9M | 2.45% | 1 |
| VERADERMICS, INC. | — | Preferred | CORP | United States | 109,305 | shares | $13.4M | 1.95% | 1 |
| Abivax SA | 00370M103 | Equity | CORP | France | 98,044 | shares | $13.1M | 1.89% | 1 |
| Immunovant Inc | 45258J102 | Equity | CORP | United States | 337,211 | shares | $13M | 1.88% | 1 |
| Tectonic Therapeutic Inc | 878972108 | Equity | CORP | United States | 370,884 | shares | $12.7M | 1.85% | 1 |
| Crinetics Pharmaceuticals Inc | 22663K107 | Equity | CORP | United States | 312,153 | shares | $11.7M | 1.69% | 1 |
| Oruka Therapeutics Inc | 687604108 | Equity | CORP | United States | 122,702 | shares | $11.7M | 1.69% | 1 |
| Equillium Inc | 29446K106 | Equity | CORP | United States | 3,631,659 | shares | $11.6M | 1.69% | 1 |
| NEUROVANCE MILESTONE INTERESTrestricted | — | Equity | CORP | United States | 34,055 | shares | $11.4M | 1.65% | 3 |
| IMMUNIC | — | Equity deriv. | OTHER | United States | 888,921 | shares | $10.9M | 1.58% | 1 |
| Edgewise Therapeutics Inc | 28036F105 | Equity | CORP | United States | 264,002 | shares | $10.7M | 1.56% | 1 |
| Axsome Therapeutics Inc | 05464T104 | Equity | CORP | United States | 43,454 | shares | $10.6M | 1.54% | 1 |
| Xenon Pharmaceuticals Inc | 98420N105 | Equity | CORP | Canada | 170,859 | shares | $10.3M | 1.50% | 1 |
| Taysha Gene Therapies Inc | 877619106 | Equity | CORP | United States | 1,496,652 | shares | $10.2M | 1.48% | 1 |
| Praxis Precision Medicines Inc | 74006W207 | Equity | CORP | United States | 30,409 | shares | $10.2M | 1.48% | 1 |
| EyePoint Inc | 30233G209 | Equity | CORP | United States | 710,173 | shares | $10.2M | 1.47% | 1 |
| Shattuck Labs Inc | 82024L103 | Equity | CORP | United States | 1,405,851 | shares | $9.8M | 1.41% | 1 |
| Summit Therapeutics Inc | 86627T108 | Equity | CORP | United States | 630,806 | shares | $9.2M | 1.33% | 1 |
| BioCryst Pharmaceuticals Inc | 09058V103 | Equity | CORP | United States | 898,336 | shares | $9M | 1.30% | 1 |
| Disc Medicine Inc | 254604101 | Equity | CORP | United States | 121,484 | shares | $8.9M | 1.29% | 1 |
| Structure Therapeutics Inc | 86366E106 | Equity | CORP | Cayman Islands | 162,217 | shares | $8.7M | 1.26% | 1 |
| Precision BioSciences Inc | 74019P207 | Equity | CORP | United States | 1,085,970 | shares | $8.5M | 1.24% | 1 |
| Arrowhead Pharmaceuticals Inc | 04280A100 | Equity | CORP | United States | 104,478 | shares | $8.5M | 1.23% | 1 |
| Ionis Pharmaceuticals Inc | 462222100 | Equity | CORP | United States | 106,455 | shares | $8.4M | 1.22% | 1 |
| Ideaya Biosciences Inc | 45166A102 | Equity | CORP | United States | 222,056 | shares | $8.3M | 1.20% | 1 |
| Newamsterdam Pharma Co NV | NL00150012L7 | Equity | CORP | Netherlands | 244,176 | shares | $8.3M | 1.20% | 1 |
| Revolution Medicines Inc | 76155X100 | Equity | CORP | United States | 43,763 | shares | $8.2M | 1.19% | 1 |
| Syndax Pharmaceuticals Inc | 87164F105 | Equity | CORP | United States | 372,766 | shares | $8.1M | 1.18% | 1 |
| Sarepta Therapeutics Inc | 803607100 | Equity | CORP | United States | 428,795 | shares | $7.7M | 1.12% | 1 |
| Adaptive Biotechnologies Corp | 00650F109 | Equity | CORP | United States | 344,653 | shares | $7.4M | 1.07% | 1 |
| Vaxcyte Inc | 92243G108 | Equity | CORP | United States | 126,674 | shares | $7.4M | 1.07% | 1 |
| Tempus AI Inc | 88023B103 | Equity | CORP | United States | 124,615 | shares | $7.2M | 1.05% | 1 |
| State Street Global Advisors | 857492706 | Short-term inv. | RF | United States | 6,953,413 | shares | $7M | 1.01% | 1 |
| Sagimet Biosciences Inc | 786700104 | Equity | CORP | United States | 847,700 | shares | $6.6M | 0.95% | 1 |
| Regeneron Pharmaceuticals Inc | 75886F107 | Equity | CORP | United States | 10,241 | shares | $6.4M | 0.93% | 1 |
| IMMUNIC INC. | — | Equity deriv. | OTHER | United States | 462,365 | shares | $6.3M | 0.91% | 1 |
| Palvella Therapeutics Inc | 697947109 | Equity | CORP | United States | 40,805 | shares | $6.2M | 0.90% | 1 |
| Vericel Corp | 92346J108 | Equity | CORP | United States | 135,240 | shares | $6M | 0.87% | 1 |
| Allogene Therapeutics Inc | 019770106 | Equity | CORP | United States | 2,731,752 | shares | $5.7M | 0.82% | 1 |
| Amgen Inc | 031162100 | Equity | CORP | United States | 15,306 | shares | $5.5M | 0.80% | 1 |
| Biohaven Ltd | VGG1110E1079 | Equity | CORP | British Virgin Islands | 365,519 | shares | $5.4M | 0.79% | 1 |
| GRAIL Inc | 384747101 | Equity | CORP | United States | 77,618 | shares | $5.3M | 0.77% | 1 |
| Codexis Inc | 192005106 | Equity | CORP | United States | 2,336,234 | shares | $5.3M | 0.77% | 1 |
| ARS Pharmaceuticals Inc | 82835W108 | Equity | CORP | United States | 651,538 | shares | $5.2M | 0.76% | 1 |
| CURASEN THERAPEUTICS, INC.restricted | — | Preferred | CORP | United States | 10,609,429 | shares | $5.2M | 0.75% | 3 |
| Amylyx Pharmaceuticals Inc | 03237H101 | Equity | CORP | United States | 285,776 | shares | $5.1M | 0.74% | 1 |
| Corbus Pharmaceuticals Holdings Inc | 21833P301 | Equity | CORP | United States | 543,719 | shares | $5.1M | 0.74% | 1 |
| Jade Biosciences Inc | 008064206 | Equity | CORP | United States | 225,693 | shares | $5M | 0.73% | 1 |
| Alnylam Pharmaceuticals Inc | 02043Q107 | Equity | CORP | United States | 16,515 | shares | $5M | 0.72% | 1 |
| Cytokinetics Inc | 23282W605 | Equity | CORP | United States | 57,613 | shares | $4.9M | 0.71% | 1 |
| ProQR Therapeutics NV | NL0010872495 | Equity | CORP | Netherlands | 2,624,861 | shares | $4.9M | 0.71% | 1 |
| Cogent Biosciences Inc | 19240Q201 | Equity | CORP | United States | 125,297 | shares | $4.8M | 0.70% | 1 |
| Arcus Biosciences Inc | 03969F109 | Equity | CORP | United States | 155,060 | shares | $4.8M | 0.69% | 1 |
| Immunic Inc | 4525EP200 | Equity | CORP | United States | 302,891 | shares | $4.7M | 0.68% | 1 |
| GeneDx Holdings Corp | 81663L200 | Equity | CORP | United States | 67,565 | shares | $4.6M | 0.67% | 1 |
| Arcutis Biotherapeutics Inc | 03969K108 | Equity | CORP | United States | 172,867 | shares | $4.5M | 0.66% | 1 |
| Oculis Holding AG | CH1242303498 | Equity | CORP | Switzerland | 324,440 | shares | $4.5M | 0.65% | 1 |
| HOTSPOT THERAPEUTICS, INC.restricted | — | Preferred | CORP | United States | 1,899,657 | shares | $4.3M | 0.63% | 3 |
| Rhythm Pharmaceuticals Inc | 76243J105 | Equity | CORP | United States | 38,140 | shares | $4.2M | 0.61% | 1 |
| Mineralys Therapeutics Inc | 603170101 | Equity | CORP | United States | 153,602 | shares | $4.1M | 0.60% | 1 |
| Inventiva SACA | 46124U107 | Equity | CORP | France | 1,093,492 | shares | $4.1M | 0.60% | 1 |
| Maze Therapeutics Inc | 578784100 | Equity | CORP | United States | 137,367 | shares | $4.1M | 0.59% | 1 |
| Palisade Bio Inc | 696389402 | Equity | CORP | United States | 1,910,205 | shares | $4M | 0.58% | 1 |
| Definium Therapeutics Inc | 24477V105 | Equity | CORP | Canada | 79,545 | shares | $3.7M | 0.54% | 1 |
| Krystal Biotech Inc | 501147102 | Equity | CORP | United States | 10,037 | shares | $3.7M | 0.54% | 1 |
| Jazz Pharmaceuticals PLC | IE00B4Q5ZN47 | Equity | CORP | Ireland | 15,453 | shares | $3.7M | 0.54% | 1 |
| Sionna Therapeutics Inc | 829401108 | Equity | CORP | United States | 82,402 | shares | $3.6M | 0.53% | 1 |
| Relay Therapeutics Inc | 75943R102 | Equity | CORP | United States | 186,561 | shares | $3.5M | 0.51% | 1 |
| Lexeo Therapeutics Inc | 52886X107 | Equity | CORP | United States | 675,092 | shares | $3.1M | 0.46% | 1 |
| Ascendis Pharma A/S | DK0060615755 | Equity | CORP | Denmark | 11,544 | shares | $3.1M | 0.45% | 1 |
| LENZ Therapeutics Inc | 52635N103 | Equity | CORP | United States | 500,700 | shares | $2.8M | 0.41% | 1 |
| Neurocrine Biosciences Inc | 64125C109 | Equity | CORP | United States | 16,247 | shares | $2.7M | 0.40% | 1 |
| Avalo Therapeutics Inc | 05338F306 | Equity | CORP | United States | 129,858 | shares | $2.4M | 0.35% | 1 |
| ELOXX PHARMACEUTICALS, INC. | — | Short-term inv. | CORP | United States | 163,602 | shares | $2.3M | 0.33% | 1 |
| ARBOR BIOTECHNOLOGIESrestricted | — | Preferred | CORP | United States | 427,918 | shares | $2.2M | 0.32% | 3 |
| AgomAb Therapeutics NV | 00860C102 | Equity | CORP | Belgium | 170,464 | shares | $2.2M | 0.32% | 1 |
| THIRD ARC BIO, INCrestricted | — | Preferred | CORP | United States | 1,050,280 | shares | $2.2M | 0.32% | 3 |
| Assembly Biosciences Inc | 045396207 | Equity | CORP | United States | 77,339 | shares | $2.1M | 0.31% | 1 |
| Immatics NV | NL0015285941 | Equity | CORP | Netherlands | 186,664 | shares | $1.9M | 0.27% | 1 |
| Vertex Pharmaceuticals Inc | 92532F100 | Equity | CORP | United States | 3,797 | shares | $1.9M | 0.27% | 1 |
| Alkermes PLC | IE00B56GVS15 | Equity | CORP | Ireland | 35,025 | shares | $1.8M | 0.27% | 1 |
| Eloxx Pharmaceuticals Inc | 29014R301 | Equity | CORP | United States | 130,900 | shares | $1.8M | 0.26% | 1 |
| QUELL THERAPEUTICSrestricted | — | Preferred | CORP | United States | 846,561 | shares | $1.8M | 0.26% | 3 |
| QLARIS BIO, INC.restricted | — | Preferred | CORP | United States | 2,166,100 | shares | $1.7M | 0.25% | 3 |
| GLYCOMINE, INC.restricted | — | Preferred | CORP | United States | 2,865,735 | shares | $1.7M | 0.25% | 3 |
| CRYSTALYS THERAPEUTICS SER Arestricted | — | Preferred | CORP | United States | 1,700,853 | shares | $1.7M | 0.25% | 3 |
| SKYHAWK THERAPEUTICS, INC. | — | Equity | CORP | United States | 45,156 | shares | $1.6M | 0.23% | 1 |
| PRECISION BIOSCIENCES | — | Equity deriv. | OTHER | United States | 336,267 | shares | $1.5M | 0.22% | 1 |
| ATALANTA THERAPEUTICSrestricted | — | Preferred | CORP | United States | 1,854,701 | shares | $1.5M | 0.21% | 3 |
| ENDEAVOR BIOMEDICINES, INC.restricted | — | Preferred | CORP | United States | 296,855 | shares | $1.4M | 0.20% | 3 |
| Rocket Pharmaceuticals Inc | 77313F106 | Equity | CORP | United States | 397,727 | shares | $1.4M | 0.20% | 1 |
| SEISMIC THERAPEUTICS, INC.restricted | — | Preferred | CORP | United States | 282,340 | shares | $1.3M | 0.18% | 3 |
| Seaport Therapeutics Inc | 81221K108 | Equity | CORP | United States | 55,039 | shares | $1.2M | 0.17% | 1 |
| NUVIG THERAPEUTICS, INCrestricted | — | Preferred | CORP | United States | 1,098,709 | shares | $1.2M | 0.17% | 3 |
| AMOLYT MILESTONErestricted | — | Preferred | CORP | United States | 6,849 | shares | $1.1M | 0.16% | 3 |
| ENGRAIL THERAPEUTICS INC. SERIrestricted | — | Preferred | CORP | United States | 2,124,646 | shares | $1M | 0.15% | 3 |
| WaVe Life Sciences Ltd | SG9999014716 | Equity | CORP | Singapore | 172,868 | shares | $1M | 0.15% | 1 |
| INCENDIA THERAPEUTICS, INC.restricted | — | Debt | CORP | United States | 996,046 | principal | $996K | 0.14% | 3 |
| INFINANT HEALTH | — | Preferred | CORP | United States | 2,932,659 | shares | $932K | 0.14% | 1 |
| SpyGlass Pharma Inc | 85220G109 | Equity | CORP | United States | 40,826 | shares | $909K | 0.13% | 1 |
| EVOMMUNE | — | Equity | CORP | United States | 58,305 | shares | $775K | 0.11% | 1 |
| INVETX MILESTONE INTERESTrestricted | — | Preferred | CORP | United States | 13,999 | shares | $714K | 0.10% | 3 |
| Kailera Therapeutics Inc | 482931102 | Equity | CORP | United States | 24,309 | shares | $536K | 0.08% | 1 |
| Odyssey Therapeutics Inc | 67613T104 | Equity | CORP | United States | 28,325 | shares | $530K | 0.08% | 1 |
| RECODE THERAPEUTICSrestricted | — | Preferred | CORP | United States | 155,959 | shares | $482K | 0.07% | 3 |
| ABCURO, INC.restricted | — | Preferred | CORP | United States | 232,252 | shares | $472K | 0.07% | 3 |
| CURASEN THERAPEUTICS CONV PNrestricted | — | ABS | CORP | United States | 441,083 | principal | $441K | 0.06% | 3 |
| Avalyn Pharma Inc | 05348Y105 | Equity | CORP | United States | 11,568 | shares | $381K | 0.06% | 1 |
| ENDEAVOR BIOMEDICINES INC.restricted | — | Preferred | CORP | United States | 54,815 | shares | $358K | 0.05% | 3 |
| HIBERCELL,INC. SERIES Crestricted | — | Preferred | CORP | United States | 719,652 | shares | $334K | 0.05% | 3 |
| Hemab Therapeutics Holdings Inc | 423494103 | Equity | CORP | United States | 8,997 | shares | $330K | 0.05% | 1 |
| HIBERCELL INC.restricted | — | Equity deriv. | OTHER | United States | 6,902,362 | shares | $320K | 0.05% | 3 |
| HIBERCELL BRIDGE NOTE | — | Debt | CORP | United States | 320,000 | principal | $320K | 0.05% | 2 |
| ABCURO INC.restricted | — | Preferred | CORP | United States | 51,403 | shares | $310K | 0.05% | 3 |
| Incendia Therapeutics, Inc.restricted | — | Preferred | CORP | United States | 832,650 | shares | $302K | 0.04% | 3 |
| HIBERCELL, INC. SERIES Brestricted | — | Preferred | CORP | United States | 1,305,163 | shares | $258K | 0.04% | 3 |
| BIOTHERYX, INC. SERIES Erestricted | — | Preferred | CORP | United States | 609,524 | shares | $246K | 0.04% | 3 |
| AVICEDA THERAPEUTICSrestricted | — | Preferred | CORP | United States | 38,906 | shares | $224K | 0.03% | 3 |
| HIBERCELL, INC.restricted | — | Debt | CORP | United States | 206,589 | principal | $207K | 0.03% | 3 |
| Quoin Pharmaceuticals Ltd | 74907L409 | Equity | CORP | Israel | 34,600 | shares | $167K | 0.02% | 1 |
| QLARIS BIO BRIDGE NOTE | — | Debt | CORP | United States | 129,525 | principal | $130K | 0.02% | 2 |
| OCULIS HOLDINGS AG | — | Equity | CORP | United States | 8,974 | shares | $124K | 0.02% | 1 |
| RECODE THERAPEUTICS, INC. | — | Debt | CORP | United States | 151,878 | principal | $75.9K | 0.01% | 3 |
| INCENDIA BRIDGE NOTE 5/2026 | — | Debt | CORP | United States | 69,798 | principal | $69.8K | 0.01% | 2 |
| CONTRA CHINOOK THERAPErestricted | 169CVR016 | Equity deriv. | OTHER | United States | 59,063 | shares | $18.9K | 0.00% | 1 |
| CONTRA FUSION PHARMACErestricted | 361CVR012 | Equity deriv. | OTHER | Canada | 3,256 | shares | $4.5K | 0.00% | 3 |
| Twist Bioscience Corp | 90184D100 | Equity | CORP | United States | 17 | shares | $1.7K | 0.00% | 1 |
| IO LIGHT HOLDINIGS, INC.restricted | — | Preferred | CORP | United States | 421,634 | shares | $42 | 0.00% | 3 |
| PRIOTHERA LIMITEDrestricted | — | Preferred | CORP | Ireland | 152,534 | shares | $17 | 0.00% | 3 |
| Willow Laboratories Inc.restricted | — | Equity | CORP | United States | 130,000 | shares | $13 | 0.00% | 3 |
| HIBERCELL, INC. SERIES Crestricted | — | Equity deriv. | OTHER | United States | 719,652 | shares | $1 | 0.00% | 3 |
| Afferent Milestone Interestrestricted | — | Equity | CORP | United States | 11,232 | shares | $0 | 0.00% | 3 |
| AMPHIVENA MILESTONE INTERESTrestricted | — | Preferred | CORP | United States | 100 | shares | $0 | 0.00% | 3 |
| ETHISMOS RESEARCH, INC. MILESTrestricted | — | Preferred | CORP | United States | 820 | shares | $0 | 0.00% | 3 |
| Options Clearing Corp. | — | Equity deriv. | OTHER | United States | -1,000 | contracts | $-318K | -0.05% | 1 |
| Options Clearing Corp. | — | Equity deriv. | OTHER | United States | -80 | contracts | $-68.4K | -0.01% | 1 |
| Options Clearing Corp. | — | Equity deriv. | OTHER | United States | -150 | contracts | $-37.1K | -0.01% | 1 |
| Options Clearing Corp. | — | Equity deriv. | OTHER | United States | -3,000 | contracts | $-15K | -0.00% | 1 |
| Options Clearing Corp. | — | Equity deriv. | OTHER | United States | -3,500 | contracts | $-14K | -0.00% | 1 |
Equities show share counts; bonds and loans show principal amount. Coupon, maturity and ratings are shown where the filing discloses them. Source: SEC N-PORT via market-data vendor re-serve, position-level.
Holdings reports on file
| Report date | Filed | Positions | Σ weight | Net assets (calc.) | Coverage |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 28, 2026 | 145 | 100.0% | $690M | full |
| Mar 31, 2026 | May 29, 2026 | 131 | 100.0% | $561M | full |
| Dec 31, 2025 | Feb 27, 2026 | 126 | 100.0% | $565M | full |
Net assets here are calculated from position values ÷ reported weights (median across positions), not a reported figure.
CEF Explorer research page for abrdn Life Sciences Investors. Figures carry their own dates and sources; a discount to NAV does not guarantee convergence or any return. This is not investment advice.